Funding will accelerate the development of kyron.bio’s proprietary glycan-engineering platform, expand the team, and fuel preclinical studies.
Founders
Dr. Emilia McLaughlin
Company Description
Kyron.bio is a biotechnology company that unlocks precision control of glycans to reduce immune side effects and improve drug efficacy in antibody therapeutics.